Introduction
============

Thoracic endovascular aortic repair (TEVAR) is becoming a preferable approach for treating thoracic aortic pathologies due to its reduced perioperative morbidity and mortality. Nonetheless, major postoperative complications have been reported. This study identified risk factors for cardiac events (CEs), defined as either myocardial infarction (MI) or cardiac arrest ≤30 days following TEVAR in descending thoracic aortic aneurysm or dissection. Understanding these risk factors should allow for appropriate resources to be given to at-risk patients to improve morbidity and mortality following TEVAR.

Cardiac events continue to remain a significant cause of morbidity and mortality following TEVAR. [@JR180023-1] [@JR180023-2] This makes it necessary to determine risk prediction models that would allow surgeons to identify at-risk patients to provide appropriate perioperative management that would minimize morbidity and improve post-TEVAR outcomes. The present study aims to identify risk factors for post-TEVAR CEs in descending thoracic aortic aneurysm or dissection to allow for optimal management of at-risk patients. It is our hope that by providing a practical risk assessment model, surgeons will have a better insight and understanding of at-risk patients to allow for more targeted perioperative management that might lead to improvement of outcomes.

Materials and Methods
=====================

Data Source and Acquisition
---------------------------

Data were retrospectively extracted from the ACS-NSQIP (American College of Surgeons National Surgical Quality Improvement Program) database from 2010 to 2016. The ACS-NSQIP is a large risk-adjusted database that was originally created in 1994 to provide 30-day surgical outcomes from the Veteran Affairs Healthcare Systems. [@JR180023-3] Currently, the database comprises over 670 hospitals around the world, with patient data collected by trained nurse reviewers. Overall, the database includes over 150 preoperative and intraoperative variables and 30-day postoperative outcomes.

Disclaimer
----------

The American College of Surgeons National Surgical Quality Improvement Program and the hospitals participating in the ACS-NSQIP are the source of the data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

Inclusion Criteria
------------------

Adult patients, 18 years and older, who underwent TEVAR were identified using current procedural terminology (CPT) codes 33880, 33881, 33883, 33886, 33889, 33891. Patients included for analyses met the following criteria: (1) indication for TEVAR was for aortic pathologies of descending thoracic aortic aneurysm or dissection, and (2) postoperative outcome variable for MI and cardiac arrest was documented and not missing. Aortic dissections could not be subgrouped into Stanford Type A or Type B since this information is not provided in the ACS-NSQIP database.

Cardiac arrest was defined as the absence of cardiac rhythm or the presence of chaotic cardiac rhythm that results in loss of consciousness requiring the initiation of any component of basic and/or advanced cardiac life support. Myocardial infarction was defined as a new transmural acute MI occurring during surgery or within 30 days following surgery as manifested by new Q-waves on ECG (electrocardiogram). [@OR180023-4]

Variable Definition
-------------------

Patient demographics included age, gender, and race (white, black, Asian, other); other race was made up of American Indians, Alaska Native, Native Hawaiian, Pacific Islander, and unknown or not reported. Other preoperative variables analyzed included body mass index, American Society of Anesthesiologists (ASA) score classification, emergency surgery, smoking (within 1 year of surgery), alcohol abuse (at least 2 drinks per day), dyspnea (at rest or with moderate exertion) ≤30 days prior to surgery, wound infection, diabetes (noninsulin dependent or insulin dependent), dependent functional health status (partially or totally dependent) ≤30 days prior to surgery, ventilator dependence ≤48 hours prior to surgery, history of chronic obstructive pulmonary disease ≤30 days prior to surgery, pneumonia, congestive heart failure, MI, angina, previous cardiac surgery or percutaneous coronary intervention, hypertension requiring medications, renal failure (acute renal failure and dialysis), transient ischemic attack, cerebral vascular accident (with or without neurological deficits), hemiplegia or paraplegia, tumor or brain occupying lesions in the central nervous system, disseminated cancer, wound infection, weight loss (≥10% of body weight in last six months), steroid use, bleeding disorder (which includes hypothrombotic conditions such as Vitamin K deficiencies, hemophilia, thrombocytopenia, and long-term anticoagulant use, though aspirin is not included within this categorization), blood transfusion of whole/packed red blood cells (PRBCs) in 72 hours prior to surgery, prior operation within 30 days, and systemic sepsis (systemic inflammatory response syndrome \[SIRS\], sepsis, and septic shock).

Available preoperative laboratory variables analyzed included serum sodium, blood urea nitrogen (BUN), creatinine, albumin, total bilirubin, aspartate aminotransferase (serum glutamic-oxaloacetic transaminase \[SGOT\]), alkaline phosphatase, white blood count (WBC), hematocrit, platelet count, prothrombin time, partial thromboplastin time, and international normalized ratio (INR). Intraoperative variables included operative and anesthesia times.

Thirty-day postoperative adverse outcomes as predictors of CEs following TEVAR were also analyzed. These included pneumonia, unplanned reintubation, pulmonary embolism, prolonged mechanical ventilation (\>48 hours following surgery), renal complications (progressive renal insufficiency, acute renal failure, urinary tract infection), neurological complications (stroke or cerebral vascular accidents, coma \>24 hours, peripheral nerve injury), packed RBC transfusions, deep venous thrombosis (DVT), surgical site infection, wound disruption, systemic sepsis, and unplanned return to the operating room.

The associations between CEs and mortality, readmission, and total length of hospital stay were also analyzed.

Statistical Analysis
--------------------

Statistical analyses were performed using SPSS software (Version 22, IBM Corporation, Chicago, IL). Descriptive analysis was reported as mean ± standard deviation for continuous data, and percentages for categorical data. Patients were grouped into those who experienced CEs and those who did not, and the risk factors were analyzed. Univariate analysis was performed using chi-square tests to correlate baseline preoperative, intraoperative, and postoperative risk factors with post-TEVAR CEs. All variables that had a *p* -value of less than 0.05 in the univariate analysis were subsequently included in the final multivariate logistic regression with CEs as the dependent variable.

This study was reviewed and approved by the Icahn School of Medicine at Mount Sinai Institutional Review Board.

Results
=======

The present study identified a total of 2,905 patients who underwent TEVAR from 2010 to 2016, 150 (5.2%) of whom experienced CEs. The overall 30-day mortality rate for all patients was 9.1%. Patients who experienced post-TEVAR CEs had a significantly high incidence of mortality (60.7 vs. 5.5%, *p*  \< 0.01) than those who did not. TEVAR was performed more frequently in descending thoracic aortic aneurysm than dissection (64.3 vs. 35.7%). There was no significant difference in the incidence of TEVAR among aortic aneurysm or dissection patients ( *p*  = 0.339). Of the patients who experienced CEs post-TEVAR, 67.3% presented with aortic aneurysm compared with 32.7% with dissection.

[Table 1](#TB180023-1){ref-type="table"} summarizes univariate analysis for patient demographics, comorbidities, and perioperative factors on risks of CEs. ASA \>3, emergency surgery, dependent functional status, preoperative ventilator dependence, renal failure, bleeding disorder, blood transfusion, systemic sepsis, BUN ≥23 mg/dL, creatinine ≥1.2, albumin \<3.5 mg/dL, total bilirubin \>1.2 mg/dL, SGOT \>35 U/L, alkaline phosphate \>126 U/L, WBC \>11 K/uL, hematocrit \<34%, INR \>1.5, and operative time \>180 minutes were significantly associated with CEs following TEVAR.

###### Univariate analysis of patient demographics, comorbidities, and perioperative factors on the risk of cardiac events following thoracic endovascular aortic repair

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                    Cardiac events\   \% Cardiac events   No Cardiac events\   \% No Cardiac events   *p* -Value
                                               *N*  = 150                            *N*  = 2,755                                
  -------------------------------------------- ----------------- ------------------- -------------------- ---------------------- ---------------------------------------------------
  *Demographics:*                                                                                                                

   Age in years (mean ± SD)                    68.9 ± 12.93      68.1 ± 13.02        0.498                                       

   BMI in kg/m ^2^ (mean ± SD)                 28.2 ± 6.83       28.7 ± 6.60         0.38                                        

  *Gender:*                                                                                                                      

   Male                                        79                52.7%               1,584                57.5%                  0.248

   Female                                      71                47.3%               1,171                42.5%                  

  *Race:*                                                                                                                        

   Black                                       36                24.0%               499                  18.1%                  0.290

   White                                       96                64.0%               1,898                68.9%                  

   Asian                                       4                 2.7%                102                  3.7%                   

   Other/Unknown                               14                9.3%                256                  9.3%                   

  BMI \> 30 kg/m ^2^                           45                30.0%               951                  34.5%                  0.260

  Age \> 65 y                                  99                66.0%               1,810                65.7%                  0.932

  *Comorbidities:*                                                                                                               

   ASA score \>3                               117               78.0%               1,438                52.2%                  \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Emergency procedure                         80                53.3%               543                  19.7%                  \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Tobacco smoking                             48                32.0%               876                  31.8%                  0.966

   ETOH                                        105               0.7%                19                   0.7%                   0.948

   Dyspnea                                     27                18.0%               504                  18.3%                  0.919

   Dependent functional status                 19                12.7%               149                  5.4%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Diabetes                                    19                12.7%               347                  12.6%                  0.980

   Ventilator dependence                       24                16.0%               69                   2.5%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   COPD                                        29                19.3                460                  16.7                   0.394

   Pneumonia                                   0                 0%                  11                   0.4%                   0.738

   CHF                                         4                 2.7%                77                   2.8%                   0.906

   Myocardial infarction                       2                 1.3%                13                   0.5%                   0.362

   Previous cardiac surgery or PCI             13                8.7%                212                  7.7%                   0.752

   Angina                                      3                 2.0%                35                   1.3%                   0.659

   Hypertension                                126               84.0%               2325                 84.4%                  0.898

   Peripheral vascular disease                 5                 3.3%                52                   1.9%                   0.411

   Renal failure                               22                14.7%               132                  4.8%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   TIA                                         2                 1.3%                41                   1.5%                   0.941

   CVA with or without neurological deficits   2                 1.3%                77                   2.8%                   0.551

   Hemiplegia/Paraplegia                       3                 2.0%                16                   0.6%                   0.109

   Tumor or brain occupying lesion in CNS      0                 0%                  3                    0.1%                   0.902

   Disseminated cancer                         1                 0.7%                22                   0.8%                   0.825

   Wound infection                             6                 4.0%                50                   1.8%                   0.052

   Steroid use                                 11                7.3%                143                  5.2%                   0.245

   Weight loss                                 4                 2.7%                55                   2.0%                   0.595

   Bleeding disorder                           31                20.7%               314                  11.4%                  \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Blood transfusion                           28                18.7%               110                  4.0%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Systemic sepsis                             38                25.3%               231                  8.4%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Surgery within 30 d of TEVAR                3                 2.0%                61                   2.2%                   0.879

  *Preoperative laboratory:*                                                                                                     

   Sodium \<135 mEg/L                          24                16.0%               328                  11.9%                  0.326

   Blood urea nitrogen ≥23 mg/dL               57                38.0%               769                  27.9%                  **0.012** [a](#FN180023-2){ref-type="table-fn"}

   Creatinine ≥1.2 mg/dL                       68                45.3%               900                  32.7%                  \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Albumin \<3.5 mg/dL                         74                49.3%               858                  31.1%                  \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Total bilirubin \>1.2 mg/dL                 14                9.3%                151                  5.5%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   SGOT \>35 U/L                               22                14.7%               224                  8.1%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Alkaline phosphate \>126 U/L                15                10.0%               184                  6.7%                   **0.015** [a](#FN180023-2){ref-type="table-fn"}

   WBC \>11 K/uL                               60                40.0%               471                  17.1%                  \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   WBC \<4.5 K/uL                              6                 4.0%                116                  4.2%                   0.992

   Hematocrit \<34%                            72                48%                 857                  31.11%                 \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Platelet \<150 K/uL                         28                18.7%               445                  16.2%                  0.640

   PTT \>35 s                                  22                14.7%               426                  15.5%                  0.170

   PT \>15 s                                   11                7.3%                118                  4.3%                   0.189

   INR \>1.5                                   14                9.3%                139                  5.1%                   **0.027** [a](#FN180023-2){ref-type="table-fn"}

  *Perioperative variables:*                                                                                                     

   Pathology type                                                                                                                

   Aneurysm                                    101               67.3%               1763                 64.0%                  0.339

   Dissection                                  49                32.7%               992                  36.0%                  

  *Intraoperative variables:*                                                                                                    

   Anesthesia time \>300 min                   15                10.0%               218                  7.9%                   0.220

   Operation time \>180 min                    79                52.7%               827                  30.0%                  \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

  *Postoperative variables:*                                                                                                     

   Pneumonia                                   29                19.3%               129                  4.7%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Unplanned reintubation                      58                38.7%               140                  5.1%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Pulmonary embolism                          1                 0.7%                11                   0.4%                   0.619

   Prolonged mechanical ventilation            56                37.3%               198                  7.2%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Renal complications                         28                18.7%               146                  5.3%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Neurological complications                  18                12.0%               107                  3.9%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Occurrences of bleeding transfusions        100               66.7%               678                  24.6%                  \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   DVT                                         8                 5.3%                41                   1.5%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   Surgical site infection                     2                 1.3%                47                   1.7%                   0.708

   Wound disruption                            0                 0%                  5                    0.2%                   0.567

   Systemic sepsis                             19                12.7%               107                  3.9%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}

   URTOR                                       34                22.7%               215                  7.8%                   \< **0.01** [a](#FN180023-2){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CHF, congestive heart failure; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; CVA, cerebral vascular accidents; DVT, deep venous thrombosis; INR, international normalized ratio; PCI, percutaneous coronary intervention; PT, prothrombin time; PTT, partial thromboplastin time; SD, standard deviation; SGOT, serum glutamic-oxaloacetic transaminase; TEVAR, thoracic endovascular aortic repair; TIA, transient ischemic attack; URTOR, unplanned return to operating room; WBC, white blood count.

Significant *p* -values that were included in multivariate logistic regression analysis.

Following TEVAR, postoperative pneumonia, unplanned reintubation, prolonged mechanical ventilation, renal complications, neurological complications, blood transfusions, DVT, systemic sepsis, and unplanned return to odds ratio (OR) were found to be significantly associated with CEs after univariate analysis

Multivariate logistic regression analysis confirmed that ASA \>3 (OR 1.71, 95% confidence interval \[CI\] 1.11--2.63, *p*  = 0.01), emergency surgery (OR 2.80, 95% CI 1.91--4.12, *p*  \< 0.01), ventilator dependence (OR 2.33, 95% CI 1.30--4.17, *p*  \< 0.01), preoperative renal failure (OR 2.53, 95% CI 1.49--4.31, *p*  \< 0.01), preoperative (OR 1.84, 95% CI 1.07--3.16, *p*  = 0.03), and postoperative (OR 4.02, 95% CI 2.69--6.01, *p*  \< 0.01) blood transfusion, WBC \>11 K/uL (OR 2.45, 1.57--3.84, *p*  \< 0.01), postoperative prolonged mechanical ventilation (OR 1.94, 95% CI 1.17--3.24, *p*  = 0.011), and unplanned reintubation (OR 5.52, 95% CI 3.46--8.82, *p*  \< 0.01) were significantly and independently associated with post-TEVAR CEs ( [Table 2](#TB180023-2){ref-type="table"} ).

###### Multivariable logistic regression identifying predictors of cardiac events following thoracic endovascular aortic repair

  Outcome                            Odds ratio   CI interval (95%)   *p* -Value   
  ---------------------------------- ------------ ------------------- ------------ ------------
  ASA \>3                            1.710        1.113               2.627        **0.014**
  Emergency case                     2.804        1.909               4.118        **\<0.01**
  Dependent functional status        1.375        0.786               2.405        0.265
  Ventilator dependence              2.326        1.296               4.174        **\<0.01**
  Renal failure                      2.534        1.491               4.308        **\<0.01**
  Bleeding disorder                  1.514        0.973               2.356        0.066
  Blood transfusion                  1.840        1.073               3.155        **0.027**
  Systemic sepsis                    1.405        0.891               2.216        0.143
  Blood urea nitrogen ≥23 mg/dL      1.006        0.594               1.705        0.981
  Creatinine ≥1.2 mg/dL              1.489        0.898               2.469        0.122
  Albumin \<3.5 mg/dL                1.538        0.953               2.482        0.078
  Total bilirubin \>1.2 mg/dL        1.178        0.605               2.295        0.630
  SGOT \>35 U/L                      1.246        0.720               2.155        0.432
  Alkaline phosphate \>126 U/L       1.079        0.575               2.025        0.813
  WBC \>11 K/uL                      2.452        1.567               3.835        **\<0.01**
  Hematocrit \<34%                   1.025        0.650               1.616        0.915
  INR \>1.5                          1.737        0.878               3.438        0.113
  Operative time \>180 min           0.958        0.401               2.288        0.922
  Pneumonia                          1.275        0.718               2.265        0.407
  Unplanned reintubation             5.520        3.455               8.820        **\<0.01**
  Prolonged mechanical ventilation   1.943        1.166               3.240        **0.011**
  Renal complications                1.564        0.875               2.796        0.131
  Neurological complications         1.209        0.634               2.306        0.565
  Bleeding transfusions              4.018        2.685               6.013        **\<0.01**
  DVT                                1.733        0.693               4.334        0.240
  Sepsis                             0.746        0.376               1.477        0.400
  URTOR                              1.094        0.518               2.311        0.815

Abbreviations: ASA, American Society of Anesthesiologists; CI, confidence interval; DVT, deep venous thrombosis; INR, international normalized ratio; OR, odds ratio; SGOT, aspartate aminotransferase; TEVAR, thoracic endovascular aortic repair; URTOR, unplanned return to operating room; WBC, white blood count.

Overall, patients who experienced CEs following TEVAR were more likely to have prolonged hospitalization (13.16 ± 14.72 vs. 8.3 ± 9.32 days, *p*  \< 0.01) and higher readmission rates (19.3 vs. 8.2%, *p*  \< 0.01; [Table 3](#TB180023-3){ref-type="table"} ).

###### Associations between cardiac events and total length of hospital stay, readmission, and mortality

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                           Cardiac events\   \% Cardiac events   No cardiac events\   \% No cardiac events   *p* -Value
                                                      *N*  = 150                            *N*  = 2755                                 
  --------------------------------------------------- ----------------- ------------------- -------------------- ---------------------- -------------
  Total length of hospital stay in days (mean ± SD)   13.2 ± 14.7       8.3 ± 9.32          \< **0.01**                                 

  Readmission                                         29                19.3%               226                  8.2%                   \< **0.01**

  Mortality                                           91                60.7%               151                  5.5%                   \< **0.01**
  ---------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: SD, standard deviation.

Discussion
==========

Prior studies have evaluated risk factors for CEs in patients undergoing major vascular surgery [@JR180023-5] [@JR180023-6] ; however, there are scarce data that provide information on perioperative risk factors for CEs in TEVAR patients. In fact, the only available study that provides cardiac risk stratification in TEVAR patients was one by Ganapathi et al [@JR180023-1] which reported on only preoperative risk factors for CEs following TEVAR at a single institution. To the best of our knowledge, our study thus becomes the first multicenter study to present a perioperative risk prediction model that allows for identifying patients at highest risk of CEs following TEVAR. In evaluating risk factors for post-TEVAR CEs, it is essential to appreciate the burden that CEs place on surgeons, patients, and the health care system. In our present study, CEs were associated with high rates of mortality, readmission, and prolonged hospitalization.

Overall, this was a large ACS-NSQIP study of 2,905 patients who underwent TEVAR for descending thoracic aortic aneurysm or dissection, of whom 150 (5.2%) experienced CEs. This 5.2% incidence of CEs is comparable with published results. [@JR180023-1] [@JR180023-2] Of the 150 patients who experienced CEs, 67.3% presented with descending thoracic aortic aneurysm compared with 32.7% with dissection. However, there were no significant differences for incidence of post-TEVAR CEs between aneurysm and dissection patients. This study\'s overall 30-day mortality rate of 9.1%, which is similar to other reported studies, [@JR180023-7] [@JR180023-8] [@JR180023-9] suggests decreased mortality compared with open surgery. In-hospital mortality for open repair of descending thoracic aortic aneurysms and/or dissections has been reported as high as 32.1%. [@JR180023-7] [@JR180023-10]

Our analysis suggests that ASA \>3, emergency surgery, dependent functional status, preoperative renal failure, leukocytosis, unplanned reintubation, and perioperative blood transfusion were independently associated with post-TEVAR CEs. After TEVAR, unplanned reintubation was an associated significant and independent risk factor.

These findings are perhaps not surprising. Generally, patients who undergo emergency major vascular surgery usually present with life-threatening conditions [@JR180023-11] that make them more susceptible to develop postoperative CEs. There is also evidence that patients who are functionally dependent have a greater medical burden, both acutely and chronically. [@JR180023-12] Scarborough et al [@JR180023-12] observed that among patients who underwent complex general or vascular surgery, functional dependency was independently associated with postoperative morbidity and mortality. Crawford et al [@JR180023-13] also observed that preoperative functional dependence is associated with all adverse postoperative complications in patients who underwent infrainguinal surgical bypass.

Similarly, preoperative renal failure has been associated with poor outcomes following major vascular and endovascular surgery. [@JR180023-14] Patients in renal failure often have significant coronary artery stenosis resulting from vascular calcification and atherosclerosis, in addition to ischemia caused by decreased oxygen delivery, [@JR180023-15] which may make them more susceptible to developing postoperative CEs. In fact, CEs have been reported concurrently as the largest single cause of mortality in dialysis patients. [@JR180023-16] [@JR180023-17] [@JR180023-18] The finding that ASA \> 3 is independently associated with CEs is expected since other reports confirm a significant association between comorbidity and adverse postoperative outcomes. [@JR180023-19] [@JR180023-20] [@JR180023-21] [@JR180023-22] [@JR180023-23]

Findings of our study suggest that perioperative blood transfusions independently increase rates of post-TEVAR CEs; however, this association should be interpreted cautiously. In fact, even though some studies demonstrate an independent association between perioperative blood transfusion and adverse postoperative outcomes, [@JR180023-24] [@JR180023-25] [@JR180023-26] [@JR180023-27] it is worthwhile to note that patients who are transfused perioperatively, in general, tend to be sicker and have several comorbid conditions including anemia which independently increase their risks of postoperative adverse outcomes. [@JR180023-28] [@JR180023-29] [@JR180023-30] [@JR180023-31] Nonetheless, that PRBCs contain proinflammatory cytokines which increase systemic inflammatory response, and have been noted to adhere to vascular endothelium leading to reduced microvascular flow and tissue hypoxia [@JR180023-25] [@JR180023-32] [@JR180023-33] demonstrate that emphasis should be placed on continuous cardiac monitoring of patients who undergo perioperative blood transfusions.

The effect of mechanical ventilation on cardiovascular performance is well-reported. [@JR180023-34] [@JR180023-35] Mechanical ventilation induces changes in intrapleural or intrathoracic pressure and lung volume and causes changes in atrial filling or preload, impedance to ventricular emptying or afterload, heart rate and myocardial contractility. [@JR180023-34] [@JR180023-35]

Unplanned reintubation is an unexpected occurrence after surgery and usually represents a deteriorating postoperative course. Patients who undergo unplanned reintubation have been reported to have higher complication rates and mortality. [@JR180023-36] [@JR180023-37] [@JR180023-38] Though reasons for unplanned reintubation for individual patients are not provided by the ACS-NSQIP database, indications usually range from emergency management of failed extubation, reintubations for emerging complications such as refractory hypotension or inability to protect airway, or emergency tracheostomy, [@OR180023-4] [@JR180023-36] all of which represent clinical deterioration.

Lastly, it is worthwhile to note that the benefits of preoperative laboratory assessments in the patients undergoing surgery have been discussed. [@JR180023-39] [@JR180023-40] In the present study leukocytosis was observed as an independent predictor of CEs after TEVAR. Preoperative leukocytosis may reflect an inflammatory response that might be associated with vascular injury and organ dysfunction, [@JR180023-39] [@JR180023-40] increasing the likelihood of CEs.

Limitations
-----------

The present study demonstrates that the cause of CEs following TEVAR is multifactorial. These results should be interpreted within the context of some limitations. First, the retrospective and observational nature of the study makes it difficult to accurately prove causation. Nonetheless, our multivariate analysis helped to control for multiple covariates. Second, the ACS-NSQIP database has its inherent limitations. The ACS-NSQIP only provides information on 30-day morbidity and mortality and does not elaborate on severity of some of the comorbid conditions. It is possible that some variables that were not significant in our study could be the predictors of post-TEVAR CEs in the long term. Similarly, the ACS-NSQIP database classifies cases based on CPT codes; hence, anatomical differences, procedural technique differences, and complication severity remain unclear. Additionally, though no statistical difference was observed in the incidence of post-TEVAR CEs between patients with aneurysm and dissection, the ACS-NSQIP database does not differentiate between Stanford Type A and Type B aortic dissections, making it difficult to account for any associations. In addition, the ACS-NSQIP database disproportionately represents data from large academic quality-seeking institutions due to the costs associated with participating and contributing to this database. [@JR180023-41] Hence, a disparity of risk factors may exist at other nonparticipating institutions, making our results nongeneralizable. Finally, ACS-NSQIP database is also subject to recording errors even though trained individuals at each institution are assigned to input data. Despite these limitations, the ACS-NSQIP database is a validated database with high inter-rater reliability that provides accurate data and allows for understanding of postoperative patient outcomes. [@JR180023-41] [@JR180023-42]

Conclusions
===========

This is the first large multicenter study that provides a practical model to predict risk factors for CEs following TEVAR. Emergency surgery, ASA \>3, dependent functional status, ventilator dependence prior to surgery, perioperative blood transfusions (preoperative and postoperative), preoperative leukocytosis, preoperative renal failure, postoperative prolonged mechanical ventilation, and postoperative unplanned reintubation are strong independent predictors of CEs following TEVAR. Recognizing these identified risk factors should allow for increased preventative approaches to decrease CEs and improve TEVAR outcomes. Future studies should prospectively evaluate these predictors to comprehensively inform surgeons on risk stratification for post-TEVAR cardiac outcomes.
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